RSS Texas Bio News

  • Top of Texas 2016: Big Exits, Ride-Sharing Leaves Austin, & More December 30, 2016
    As 2016 comes to an end, let’s take a look at some of the more notable stories from Xconomy Texas over the past year. What follows is my highly subjective list of news that we covered in 2016. Notable exits and fundraises: —San Antonio cloud computing company Rackspace was bought by New York private equity […]
    Angela Shah
  • ‘Creepy Bird’ Anyone? Meet San Antonio’s Retro Video Game Developer December 30, 2016
    San Antonio—Video games are big business, and highly dynamic. From the Xbox to virtual reality, how players play has changed quite a bit since the Atari and the NES brought home gaming to the masses. One San Antonio video game developer is riding a wave of renewed interest in older gaming systems, starting a business […]
    David Holley
  • Despite Political Rhetoric, Staff Diversity Remains a Top Priority December 30, 2016
    I don’t think the election of Donald Trump as president does much to bolster those in tech working on creating a more inclusive and diverse industry, but I will continue to be a champion for it nonetheless. Specifically, I’ve ended 2016 by doubling our team at Localeur and introducing an Advisory Board, both of which […]
    Joah Spearman
  • Political Focus on Rust Belt Could Help Boost VC Investment December 29, 2016
    Much has been written in the tech industry as a result of the Presidential election. Many coastal VCs and entrepreneurs believe that Trump’s America-first, anti-immigration platform could put the brakes on the venture industry’s core globalization strategies. While this may be true, regardless of which candidate you supported, most would agree that with chaos and […]
    Blair Garrou
  • 6 Cybersecurity Predictions for 2017: Ransomware, Skills Gap & More December 28, 2016
    In 2016, we saw cyber attacks increasingly shift from external breaches of confidential data to internal disruption of data and services, as attackers used distributed denial of service (DDoS) or encryption to hold businesses hostage. Attackers continue to focus more on exploiting users than technology. Users are often unaware and uneducated about the potential risks, […]
    James Maude
  • East Coast Silicon Valley December 27, 2016
    “You never change things by fighting the existing reality. To change something, build a new model that makes the existing model obsolete.” – R. Buckminster Fuller Reinvention A few months ago I was talking to executives in charge of innovation at a large U.S. bank. “Our biggest problem is that we look at all this new […]
    Dan Deac
  • Immigration Restrictions, Lack of Healthcare Could Imperil Innovation December 27, 2016
    It’s hard to predict what effect the new administration will have, since we have very little information on any concrete policies they plan to enact. We do know a few things—namely, they are anti-Obamacare and anti-immigration. Decreasing the number of visas granted to highly skilled workers (a likely possibility given Steve Bannon’s comments on Silicon […]
    Shion Deysarkar
  • Ambiq Micro Lands $2,458,624 New Financing Round December 26, 2016
    Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=b14cce5b-17e6-45ad-8174-a48eded4efe6 Date 12/26/2016 Company Name Ambiq Micro Mailing Address 11305 4 Points Drive West Lake Hills, TX 78726 USA Company Description A semiconductor company with a breakthrough patented technology, Subthreshold Power Optimized Technology (SPOT) that dramatically reduces the amount of power consumed by ICs. Website http://www.ambiqmicro.com Transaction Type Venture Equity Transaction Amount […]
    VentureDeal
  • Texas Roundup: “1st & Future,” “Pink Tank” Pitch Contests, & More December 23, 2016
    As we approach Santa’s annual visit—are your milk and cookies ready?—let’s get caught up with the latest innovation news from Xconomy Texas: —The National Football League has teamed up with the Texas Medical Center to sponsor the 1st & Future startup pitch competition Feb. 4, the day before the Super Bowl takes place in Houston. […]
    Angela Shah
  • Bio Roundup: Crazy ’16, Trials of ’17, Senate on Drugs & More December 23, 2016
    You’ve probably seen the Internet memes. “When 2016 started, I looked like this. [Insert picture of young Leo DiCaprio.] Now I look like this. [Leo, with mountain beard, after mud-wrestling with a grizzly in The Revenant.]” In life science terms, let’s just say all our telomeres feel a lot shorter than 12 months ago. The […]
    Alex Lash

RSS National Bio News

  • Monthly News Roundup - February 2017 February 28, 2017
    FDA Approves Once-Daily Qtern Tablets for Adults with Type 2 Diabetes The U.S. Food and Drug Administration (FDA) has cleared AstraZeneca’s Qtern (dapagliflozin and saxagliptin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor and dipeptidyl...
  • FDA Clears Test to Help Manage Antibiotic Treatment for Lower Respiratory Tract Infections and Sepsis February 23, 2017
    February 23, 2017 -- The U.S. Food and Drug Administration today cleared the expanded use of the Vidas Brahms PCT Assay to help health care providers determine if antibiotic treatment should be started or stopped in patients with lower respiratory...
  • FDA Allows Marketing of Test to Identify Organisms That Cause Bloodstream Infections and Provide Antibiotic Sensitivity Results February 23, 2017
    February 23, 2017 -- The U.S. Food and Drug Administration today allowed marketing of the PhenoTest BC Kit, performed on the Pheno System. This is the first test to identify organisms that cause bloodstream infections and provide information about...
  • Louisiana Drug and Dietary Supplement Maker Ordered to Cease Operations Due to Federal Violations February 21, 2017
    February 21, 2017 -- On Friday, U.S. District Judge Robert G. James for the U.S. District Court for the Western District of Louisiana entered a consent decree of permanent injunction against Pick and Pay Inc./Cili Minerals, a manufacturer and...
  • Monthly News Roundup - January 2017 January 31, 2017
    Trulance Cleared by FDA for Chronic Idiopathic Constipation (CIC) The U.S. Food and Drug Administration (FDA) has approved Synergy’s Trulance (plecanatide), a uroguanylin analog for the treatment of chronic idiopathic constipation (CIC)....
  • FDA Approves Xyrem (sodium oxybate) Oral Solution Generic with a REMS Program January 18, 2017
    January 18, 2017 -- The FDA has approved the first generic version of Xyrem (sodium oxybate) Oral Solution, to treat cataplexy and excessive daytime sleepiness in patients with narcolepsy, which is a potentially debilitating disease. Cataplexy is a...
  • Monthly News Roundup - December 2016 December 31, 2016
    Biogen’s Spinraza Approved for Spinal Muscular Atrophy The U.S. Food and Drug Administration (FDA) has cleared Biogen's Spinraza (nusinersen), the first drug for spinal muscular atrophy (SMA), a rare and often fatal genetic disease affecting...
  • Monthly News Roundup - November 2016 November 30, 2016
    Novo Nordisk’s Xultophy 100/3.6 FDA-Approved for Type 2 Diabetes This month the U.S. Food and Drug Administration (FDA) approved Novo Nordisk’s Xultophy 100/3.6 (insulin degludec and liraglutide), a once-daily injection of insulin degludec...
  • Monthly News Roundup - October 2016 October 31, 2016
    Merck’s Zinplava Approved to Fend Off Return of Clostridium Difficile Zinplava (bezlotoxumab) has been FDA-approved to reduce the recurrence of Clostridium difficile infection (CDI) in adults who are receiving antibacterial drug treatment for...
  • Monthly News Roundup - September 2016 September 29, 2016
    Amjevita, a Biosimilar to Humira, Wins FDA Approval Amgen’s Amjevita (adalimumab-atto) is the first adalimumab (Humira) biosimilar approved by the U.S. Food and Drug Administration (FDA) and is used for the treatment of seven inflammatory...
  • Monthly News Roundup - August 2016 August 31, 2016
    FDA Approves Erelzi: Sandoz’s Biosimilar For Enbrel A third U.S. biosimilar has been FDA-approved; this time it’s Erelzi (etanercept-szzs), a biosimilar to Amgen’s tumor necrosis factor (TNF) blocker Enbrel. Sandoz’s Erelzi is the first...
  • FDA Approves First Generic Version of Widely Used Influenza Drug Tamiflu August 4, 2016
    On August 3, 2016, the U.S. Food and Drug Administration approved the first generic version of Tamiflu (oseltamivir phosphate), a widely used medication for the treatment of the flu (influenza A and B) in patients two weeks of age and older who have...

RSS Worldwide Bio News

  • Excessive Levels of Satiety Hormone Leptin May Contribute to Severity of SMA, Study Finds March 16, 2017
    This post was originally published on this site Nearly half of young people with spinal muscular atrophy (SMA) — and especially those who are underweight — have abnormally high levels of leptin, a metabolic hormone linked to both disease severity and limited mobility, says a new study. The findings show that SMA is associated with abnormal metabolic processes, […]
    Magdalena Kegel
  • After Long Wait, Zinbryta Gains Approval in Areas of the UK March 16, 2017
    This post was originally published on this site News that daclizumab, brand name Zinbryta, has been given the go-ahead to be available through the U.K.’s National Health Service (NHS) for treating relapsing MS, at least in part of the country, is good news. But why has the decision taken so long? Possibly, because the first decision, […]
    admin
  • Discovery of T-cells’ Role in Myelin Regeneration Could Lead to Therapies That Mimic Processes March 16, 2017
    This post was originally published on this site Regulatory T-cells in the central nervous system trigger the maturation of stem cells that increase the production of myelin at injured neurons — a discovery that places the idea of regeneration in multiple sclerosis (MS) in a whole new light. Myelin is a substance essential to the […]
    Magdalena Kegel
  • Acorda Launches Interactive and Talking ‘MS Awareness Facts’ Alexa Service for March March 16, 2017
    This post was originally published on this site In recognition of multiple sclerosis (MS) awareness month, Acorda Therapeutics has launched its Alexa skill, called MS Awareness Facts.  The interactive voice-controlled service allows users to ask Amazon Alexa for information regarding MS and its debilitating symptoms. Amazon Alexa is a cloud-based service that enable customers to interact in […]
    admin
  • #MSAwarenessMonth: Do You Know About the MS Iceberg? March 16, 2017
    This post was originally published on this site Multiple sclerosis is often a confusing disease to others, since very few of the symptoms MS patients experience are visible to others. This “iceberg” effect means that many are misunderstood and their suffering vastly underestimated. Find out more about Multiple Sclerosis Awareness Month here.  What is the tip of […]
    Wendy Henderson
  • Walk In, Roll Out: The Conundrum of Cardio Exercise with MS March 16, 2017
    This post was originally published on this site In pursuit of an answer for breathing difficulty The MRI of my cervical and thoracic spine showed no active lesions last week. That was good news. Other recent and historical tests never resulted in any explanation as to why I have a persistent cough, hoarseness, and recently […]
    admin
  • Benefits Seen for Rubraca in Certain Advanced Ovarian Cancers in Phase 2 Study March 15, 2017
    This post was originally published on this site Ovarian cancer patients with a BRCA mutation who responded to their last line of platinum-based chemotherapy are more likely to benefit from Rubraca (rucaparib) than those resistant or refractory to platinum treatment, according to new data from the Phase 2 ARIEL2 study. Results were recently presented at the […]
    admin
  • Benefits Seen for Rubraca in Certain Advanced Ovarian Cancers in Phase 2 Study March 15, 2017
    This post was originally published on this site Ovarian cancer patients with a BRCA mutation who responded to their last line of platinum-based chemotherapy are more likely to benefit from Rubraca (rucaparib) than those resistant or refractory to platinum treatment, according to new data from the Phase 2 ARIEL2 study. Results were recently presented at the […]
    admin
  • MS and the Fear of Missing Out March 15, 2017
    This post was originally published on this site A couple of weeks ago I had a curious encounter with the friend of a friend. I live in a small town. In some ways we’re all at least neighbors. Huddled in a small group at the local grocery store, we were chatting about our experiences with […]
    admin
  • CKD Patients Don’t Benefit from Intensive Blood Pressure Control, Study Says March 15, 2017
    This post was originally published on this site Blood pressure treatment below the standard accepted level does not offer an additional benefit for renal function in patients with chronic kidney disease (CKD) without diabetes, according to researchers. However, nonblack patients or those with higher levels of proteinuria (an abnormal amount of protein in the urine) […]
    admin